Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nazartinib in EGFR-mutant NSCLC
NCT02108964Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of nazartinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jun 2014; status: completed.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02108964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108964.